Janet. M. Hock

Janet. M. Hock

Auto-generated profile, based on publicly available information

Janet. M. Hock

Maine Institute for Human Genetics and Health, Bangor, ME, USA

Research Focus & Metrics

Academic Career Length

56Years (1971-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 1991 in Science
Verified
Journal Article
Closed access
PDF file
HJHarald Jüppner
Harald Jüppner
AAAbdul-Badi Abou-Samra
Abdul-Badi Abou-Samra
MFMason Freeman
Mason Freeman
XKXiang F. Kong
Xiang F. Kong
ESErnestina Schipani
Ernestina Schipani
AEAl. Et
Al. Et
The complementary DNA encoding a 585-amino acid parathyroid hormone-parathyroid hormone-related peptide (PTH-PTHrP) receptor with seven potential membrane-spanning domains was cloned by COS-7 expression using an opossum kidney cell complementary DNA (cDNA) library. The expressed receptor binds PTH and PTHrP with equal affinity, and both ligands equivalently stimulate adenylate cyclase. Striking homology with the calcitonin receptor and lack of homology with other G protein-linked receptors indicate that receptors for these calcium-regulating hormones are related and represent a new family.

1 January 1988 in Endocrinology
Verified
Journal Article
Closed access
JHJanet M. Hock
Janet M. Hock
MCMichael Centrella
Michael Centrella
ECErnesto Canalis
Ernesto Canalis
The effects of insulin-like growth factor-I (IGF-I) and insulin on bone matrix synthesis and bone cell replication were studied in cultured 21-day-old fetal rat calvariae. Histomorphometry techniques were developed to measure the incorporation of [2,3-3H]proline and [methyl-3H]thymidine into bone matrix and bone cell nuclei, respectively, using autoradiographs of sagittal sections of calvariae cultured with IGF-I, insulin, or vehicle for up to 96 h. To confirm an effect on bone formation, IGF-I was also studied for its effects on [3H]proline incorporation into collagenase-digestible protein (CDP) and noncollagen protein and on [3H]thymidine incorporation into acid-precipitable material (DNA). IGF-I at 10(-9)-10(-7) M significantly increased the rate of bone matrix apposition and CDP after 24 h by 45-50% and increased cell labeling by 8-fold in the osteoprogenitor cell zone, by 4-fold in the osteoblast cell zone, and by 2-fold in the periosteal fibroblast zone. Insulin at 10(-9)-10(-6) M also increased matrix apposition rate and CDP by 40-50%, but increased cell labeling by 2-fold only at a concentration of 10(-7) M or higher and then only in the osteoprogenitor cell zone. When hydroxyurea was added to IGF-I-treated bones, the effects of IGF-I on DNA synthesis were abolished, but the increase in bone matrix apposition induced by IGF-I was only partly diminished. In conclusion, IGF-I stimulates matrix synthesis in calvariae, an effect that is partly, although not completely, dependent on its stimulatory effect on DNA synthesis.

20 July 2010 in Psycho-Oncology
Verified
Journal Article
Closed access
PDF file
MAMelissa A. Alderfer
Melissa A. Alderfer
KLKristin A. Long
Kristin A. Long
ELE. Anne Lown
E. Anne Lown
AMAnna L. Marsland
Anna L. Marsland
NONancy L. Ostrowski
Nancy L. Ostrowski
LELinda J. Ewing
Linda J. Ewing

1 November 2004 in Bone
Verified
Journal Article
Closed access
MAMatthew R. Allen
Matthew R. Allen
JHJanet M. Hock
Janet M. Hock
DBDavid B. Burr
David B. Burr

1 January 1992 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
JHJ.M. Hock
J.M. Hock
IGI. Gera
I. Gera
The role of resorption in the anabolic response of bone to parathyroid hormone (PTH) is not well understood. In contrast to the increase in bone mass induced by intermittent PTH in intact rats, continuous infusion of PTH into thyroparathyroidectomized (TPTX) rats failed to increase bone volume. The objectives of this study were to determine if continuous infusions of low doses of PTH were anabolic in intact rats and if inhibition of resorption would enhance or block an anabolic action of PTH. Young male rats were treated with either continuous infusion or intermittent injections of hPTH-(1-34) for 12 days. In experiment 1, PTH, infused daily at 4 μg per 100 g, increased femur calcium and dry weight. Unlike infusion of 8 μg PTH, which did not alter bone mass, intermittent PTH at 8 μg was anabolic and increased bone mass by increasing trabecular thickness and number. Infusion of 16 μg induced hypercalcemia and death. In experiment 2, lower dose daily infusions of 0.25–4 μg PTH per 100 g did not increase bone mass. In experiment 3, in rats pretreated with dichloromethylene diphosphonate (CI2MDP) to inhibit resorption and subsequently exhibiting decreased bone formation, PTH, irrespective of the method of administration, reversed the inhibitory effects of Cl2MDP on bone formation. Thus, intermittent and continuous PTH increase bone formation independently of effects on bone resorption, but only intermittent PTH increases bone mass consistently.

1 January 2001 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
DBDavid B. Burr
David B. Burr
THToru Hirano
Toru Hirano
CTCharles H. Turner
Charles H. Turner
CHCharlotte Hotchkiss
Charlotte Hotchkiss
RBRobert Brommage
Robert Brommage
JHJanet M. Hock
Janet M. Hock
Cortical porosity in patients with hyperparathyroidism has raised the concern that intermittent parathyroid hormone (PTH) given to treat osteoporotic patients may weaken cortical bone by increasing its porosity. We hypothesized that treatment of ovariectomized (OVX) cynomolgus monkeys for up to 18 months with recombinant human PTH(1–34) [hPTH(1–34)] LY333334 would significantly increase porosity in the midshaft of the humerus but would not have a significant effect on the strength or stiffness of the humerus. We also hypothesized that withdrawal of PTH for 6 months after a 12-month treatment period would return porosity to control OVX values. OVX female cynomolgus monkeys were given once daily subcutaneous (sc) injections of recombinant hPTH(1–34) LY333334 at 1.0 μg/kg (PTH1), 5.0 μg/kg (PTH5), or 0.1 ml/kg per day of phosphate-buffered saline (OVX). Sham OVX animals (sham) were also given vehicle. After 12 months, PTH treatment was withdrawn from half of the monkeys in each treatment group (PTH1-W and PTH5-W), and they were treated for the remaining 6 months with vehicle. Double calcein labels were given before death at 18 months. After death, static and dynamic histomorphometric measurements were made intracortically and on periosteal and endocortical surfaces of sections from the middiaphysis of the left humerus. Bone mechanical properties were measured in the right humeral middiaphysis. PTH dose dependently increased intracortical porosity. However, the increased porosity did not have a significant detrimental effect on the mechanical properties of the bone. Most porosity was concentrated near the endocortical surface where its mechanical effect is small. In PTH5 monkeys, cortical area (Ct.Ar) and cortical thickness (Ct.Th) increased because of a significantly increased endocortical mineralizing surface. After withdrawal of treatment, porosity in PTH1-W animals declined to sham values, but porosity in PTH5-W animals remained significantly elevated compared with OVX and sham. We conclude that intermittently administered PTH(1–34) increases intracortical porosity in a dose-dependent manner but does not reduce the strength or stiffness of cortical bone.